Cantor Fitzgerald Raises Earnings Estimates for CG Oncology

CG Oncology, Inc. (NASDAQ:CGON) – Stock analysts at Cantor Fitzgerald lifted their FY2026 earnings per share (EPS) estimates for shares of CG Oncology in a research note issued on Monday, November 17th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($3.33) for the year, up from their prior forecast of ($3.80). Cantor Fitzgerald currently has a “Overweight” rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

Other equities research analysts have also issued research reports about the stock. Guggenheim assumed coverage on shares of CG Oncology in a report on Tuesday, October 7th. They issued a “buy” rating and a $90.00 target price on the stock. Zacks Research raised CG Oncology from a “strong sell” rating to a “hold” rating in a report on Monday, September 1st. Morgan Stanley raised their target price on CG Oncology from $56.00 to $79.00 and gave the company an “overweight” rating in a report on Wednesday, September 17th. Royal Bank Of Canada lifted their target price on CG Oncology from $53.00 to $61.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Piper Sandler initiated coverage on CG Oncology in a report on Monday, August 18th. They set an “overweight” rating and a $55.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $59.50.

CG Oncology Trading Down 4.4%

CG Oncology stock opened at $40.71 on Wednesday. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of -19.96 and a beta of 1.32. The firm’s fifty day moving average price is $40.21 and its two-hundred day moving average price is $31.23. CG Oncology has a 1-year low of $14.80 and a 1-year high of $45.56.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.57) EPS for the quarter, meeting analysts’ consensus estimates of ($0.57). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 21.67%. The business had revenue of $1.51 million during the quarter, compared to analyst estimates of $0.07 million.

Institutional Investors Weigh In On CG Oncology

A number of hedge funds have recently made changes to their positions in the business. Wesbanco Bank Inc. bought a new position in CG Oncology during the second quarter valued at about $702,000. Swiss National Bank raised its position in CG Oncology by 1.9% in the first quarter. Swiss National Bank now owns 81,100 shares of the company’s stock worth $1,986,000 after acquiring an additional 1,500 shares during the period. CWM LLC boosted its stake in CG Oncology by 193.5% in the second quarter. CWM LLC now owns 6,193 shares of the company’s stock valued at $161,000 after acquiring an additional 4,083 shares during the last quarter. Woodline Partners LP boosted its stake in CG Oncology by 21.5% in the first quarter. Woodline Partners LP now owns 764,357 shares of the company’s stock valued at $18,719,000 after acquiring an additional 135,472 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of CG Oncology by 8.7% during the 1st quarter. Northern Trust Corp now owns 471,764 shares of the company’s stock valued at $11,554,000 after acquiring an additional 37,904 shares during the period. 26.56% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other CG Oncology news, Director Brian Guan-Chyun Liu bought 1,515,151 shares of CG Oncology stock in a transaction dated Thursday, September 11th. The stock was bought at an average cost of $33.00 per share, with a total value of $49,999,983.00. Following the completion of the acquisition, the director directly owned 1,515,151 shares in the company, valued at approximately $49,999,983. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director James Mulay sold 27,015 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $31.53, for a total value of $851,782.95. The SEC filing for this sale provides additional information. Insiders have sold 175,359 shares of company stock worth $5,553,214 over the last 90 days. 7.40% of the stock is currently owned by corporate insiders.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.